AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00704925
Drug: 3, 4 DAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with clinically-confirmed LEMS will receive 3, 4 DAP by mouth in slowly increasing doses. Treatment will begin with 5 mg three times a day and will increase by 50% every two weeks to 10-15 mg three to six times a day, as clinically needed, and if tolerated.
Trial: NCT05079360
Drug: Sabizabulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32mg each day by mouth
Trial: NCT05187793
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment including:~* Baricitinib, 4 mg, film coated tablets~* Favipiravir, 200 mg, film coated tablets~* Dexamethasone IV or IM OR Methylprednisolone IV
Trial: NCT04562116
Drug: CYP 450 Substrates
RxNorm normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CYP substrates (Caffeine, Warfarin Sodium, Midazolam, Omeprazole, and Metoprolol Tartrate) will administered orally at Week 0 (Day 1) and Week 10 as per the commercially available prescribing information.
Trial: NCT04242147
Drug: KD033 (SAR445710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for infusion Route of administration: intravenous (IV)
Trial: NCT05069649
Drug: Ergoferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral use.
Trial: NCT05069649
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral use.
Trial: NCT05419856
Drug: 4P-004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single intraarticular administration in the knee joint
Trial: NCT05419856
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single intraarticular administration in the knee joint
Trial: NCT05539651
Drug: RBD5044
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously Administered RBD5044 in Healthy Subjects
Trial: NCT05539651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously Administered Placebo in Healthy Subjects
Trial: NCT05945888
Drug: Placebo matching BI 3000202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BI 3000202
Trial: NCT00002219
Drug: Levocarnitine
RxNorm normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05635227
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule identical to capsule containing olanzapine
Trial: NCT06135584
Drug: Other drugs
RxNorm normalized name: Other drugs for bile therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese patent medicine or hypoglycemic drugs other than pioglitazone metformin tablets, pioglitazone, metformin, GLP1
Trial: NCT01245725
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be dosed as an i.v. bolus followed by an i.v. infusion during a percutaneous coronary intervention plus two hours after the procedure.~Patients will receive placebo on a background of oral anti-platelet agent(s) and either unfractionated heparin (50U/kg and repeat dosing guided per guidelines) or bivalirudin as per local practice and physician discretion.
Trial: NCT05753462
Drug: Phase 1, SQY51
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQY51 is administered by intravenous infusion.
Trial: NCT05753462
Drug: Phase 2a, SQY51 (cohort 1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQY51 is administered by intravenous infusion at dose 1
Trial: NCT05753462
Drug: Phase 2a, SQY51 (cohort 2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQY51 is administered by intravenous infusion at dose 2.
Trial: NCT05753462
Drug: Phase 2a, SQY51 (cohort 3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQY51 is administered by intravenous infusion at dose 3.
Trial: NCT05324995
Drug: Multimodal Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Multimodal Drug group received morphine, epinephrine, and ketorolac (n=48), The epinephrine group (placebo group) (n=49) received 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) peri-articulary,and the celecoxib group(control group)(n=49) recieved 400mg celecoxib orally
Trial: NCT05324995
Drug: epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The second group received 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) peri-articulary
Trial: NCT05324995
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The third group administered celecoxib (200 mg) orally immediately before the surgery
Trial: NCT05195112
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline
Trial: NCT06645886
Drug: KQB198
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral KQB198
Trial: NCT05779657
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous isotonic saline 0.4 ml/kg (max 12 ml) over 5 minutes
Trial: NCT05035888
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An initial prophylactic bolus dose of norepinephrine (3μg) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 μg according to the responses of previous patients according to the up-down sequential allocation.
Trial: NCT04933292
Drug: Methylprednisolone and Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methylprednisolone combination of mycophenolate mofetil
Trial: NCT04933292
Drug: Methylprednisolone and azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methylprednisolone combination of azathioprine
Trial: NCT06167486
Drug: SG2918
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The SG2918 will be administrated by intravenous infusion every 3 weeks
Trial: NCT06021808
Drug: Novel oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients with creatinine clearance ≥50 ml/min, oral rivaroxaban 20 mg daily was administered, whereas for patients with creatinine clearance between 30-49 ml/min, oral rivaroxaban 15 mg daily was administered.
Trial: NCT00689806
Drug: Lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lovastatin 20 mg extended release (or placebo) by mouth once daily for weeks 1-4. Liver function test will be checked at week 4 follow up visit. If LFTs are not \> 3 times the upper limit of normal, then the subject will have the dose of extended release lovastatin increased to 60 mg once a day for weeks 4-12
Trial: NCT00689806
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo by mouth once daily for weeks 1-4.
Trial: NCT00002139
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03940807
Drug: 11.25mg GnRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-long protocol group women will receive one intra-muscular administration of 11.25 mg GnRH agonist (triptorelin acetate) on the luteal phase of their menstrual cycle. Ovarian stimulation will be started after 90 days desensitization.~After the desensitization period, all patients will undergo standardized ovarian stimulation, follicular aspiration, fertilization of all oocytes using either standard insemination or ICSI according to the features of sperm examination, fresh embryo transfer and luteal phase support.
Trial: NCT03940807
Drug: 0.1 mg GnRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long protocol group women will receive a 15-days pituitary down-regulation protocol that consists of daily subcutaneous injection of 0.1mg of GnRH agonist (triptorelin acetate) started on the luteal phase of their menstrual cycle.~Ovarian stimulation will begin after 15 days desensitization. After the desensitization period, all patients will undergo standardized ovarian stimulation, follicular aspiration, fertilization of all oocytes using either standard insemination or ICSI according to the features of sperm examination, fresh embryo transfer and luteal phase support.
Trial: NCT03940807
Drug: 25 µg transdermal oestradiol
RxNorm normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Add back therapy (transdermal estradiol, 25μg twice a week) will be administrated throughout down-regulation period.
Trial: NCT06455722
Drug: [68Ga]Ga-P15-041
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of one dose of 111-148 MBq (3-4 mCi) \[68Ga\]Ga-P15-041. Tracer doses of \[68Ga\]Ga-P15-041 will be used to image lesions by PET/CT.
Trial: NCT05175274
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT04575519
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 2 months treatment: 2 tablets during 4 weeks + 1 tablet during 4 weeks
Trial: NCT04575519
Drug: ASA group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid 2 months treatment: 2 tablets during 4 weeks (600 mg daily) + 1 tablet during 4 weeks (300 mg daily)
Trial: NCT04575519
Drug: IBU group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 2 months treatment: 2 tablets during 4 weeks (800 mg daily) + 1 tablet during 4 weeks (400 mg daily)
Trial: NCT05081921
Drug: HA administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of hyaluronic acid (HA) will be administrated intraarticularly as an active control in patients enrolled in Control Patients groups.
Trial: NCT04853927
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proxalutamide 300mg q.d placebo
Trial: NCT06556485
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy
Trial: NCT06573008
Drug: GP681 40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 20mg tablets taken orally
Trial: NCT06573008
Drug: GP681 Simulant
RxNorm normalized name: STAPHYLOCOCCUS SIMULANS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matching GP681 40mg
Trial: NCT05741476
Drug: DBV712
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBV712 250 mcg epicutaneous system.
Trial: NCT05111145
Drug: ELX/TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination tablets for oral administration.
Trial: NCT04843631
Drug: BFI-751
RxNorm normalized name: BFI PWDR,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single use vial, solution
Trial: NCT04843631
Drug: EU-STELARA®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-filled syringe, solution
Trial: NCT04843631
Drug: US-STELARA®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-filled syringe, solution
Trial: NCT05531552
Drug: clinical pharmacy application
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: assessment clinical pharmacist in management of CAD and ICU patients.
Trial: NCT04966325
Drug: LC350189 200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will receive an LC350189 200mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
Trial: NCT04966325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will receive a Placebo as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
Trial: NCT04966325
Drug: LC350189 600mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will receive an LC350189 600mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
Trial: NCT04926116
Drug: AK3280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
Trial: NCT04926116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
Trial: NCT05298475
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn)
Trial: NCT05298475
Drug: PCSK9 inhibitor
RxNorm normalized name: PCSK9 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 injection of PCSK9 inhibitor once a month SC
Trial: NCT05298475
Drug: PCSK9 inhibitor
RxNorm normalized name: PCSK9 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 injection of PCSK9 inhibitor twice a month SC
Trial: NCT05817461
Drug: AZD0780 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, fasted
Trial: NCT05817461
Drug: [14C]AZD0780 Solution for Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous
Trial: NCT05817461
Drug: [14C]AZD0780 Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, fasted
Trial: NCT06466525
Drug: LBT-3627
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic peptide
Trial: NCT06466525
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle
Trial: NCT06326606
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule with no active ingredients
Trial: NCT05670912
Drug: Placebo Comparator of Wei Li Bai capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The distribution ratio between the groups was 1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the active group or placebo group will be determined by the randomized system.
Trial: NCT04770493
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo (sugar pill)
Trial: NCT06567002
Drug: MK-6552
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Administration
Trial: NCT05588440
Drug: Bridging Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bridging therapy can be oral chemotherapy or IV radiotherapy/chemotherapy per institution's guidelines
Trial: NCT06290388
Drug: 23ME-01473
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23Me-01473 given by intravenous infusion
Trial: NCT06060210
Drug: normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50-ml Saline
Trial: NCT04594746
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo to be given as a 10-capsule dose pack and ingested in a single sitting with food
Trial: NCT06710080
Drug: Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]
RxNorm normalized name: ICOSAPENT ETHYL 1000 mg ORAL CAPSULE [Vascepa]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to the treatment arm will receive Vascepa 1000mg twice a day for 6 months.
Trial: NCT06710080
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily
Trial: NCT06714981
Drug: Opioid Free Anaesthesia
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients received opioid free anesthesia
Trial: NCT06714981
Drug: Opioid based Anesthesia
RxNorm normalized name: Opioid anesthetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients received opioid based anesthesia
Trial: NCT05245708
Drug: intranasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will be assigned to intranasal placebo.
Trial: NCT06719024
Drug: Aqueous cream
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a thin layer of the assigned topical to the selected lesions twice daily, maintaining at least an 8-hour interval between applications
Trial: NCT00010465
Drug: Botanicals
RxNorm normalized name: Vicks Children's Botanicals Cough Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06715826
Drug: [68Ga]Ga-NOTA-T4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients will receive 0.05-0.1mCi/kg of \[68Ga\]Ga-NOTA-T4. ImmunoPET/CT imaging will be acquired 1 hour after \[68Ga\]Ga-NOTA-T4 injection.
Trial: NCT06715826
Drug: [18F]F-RESCA-T4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-T4. ImmunoPET/CT imaging will be acquired 1 hour after \[18F\]F-RESCA-T4 injection.
Trial: NCT06715826
Drug: [68Ga]Ga-DOTA-H2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients will receive 0.05-0.1mCi/kg of \[68Ga\]Ga-DOTA-H2D3. ImmunoPET/CT imaging will be acquired 1 hour after \[68Ga\]Ga-DOTA-H2D3 injection.
Trial: NCT06715826
Drug: [18F]F-RESCA-RB14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-RB14. ImmunoPET/CT imaging will be acquired 1 hour after \[18F\]F-RESCA-RB14 injection.
Trial: NCT04852458
Drug: Intravenous (IV) hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants (20) will be given IV hydrocortisone within 6-12 hours of the traumatic event.~90 - 150 mg. of intravenous hydrocortisone dosing regimen based on participant weight: 90mg will be administrated to participants weighing 45-59kg. 100mg will be administrated to participants weighing 60-69kg. 120mg will be administrated to participants weighing 70-89kg. 140mg will be administrated to participants weighing 90-99kg. 150mg will be administrated to participants weighing 100-120kg.
Trial: NCT04772209
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dialysis catheter lumen will be filled (locked) by classic heparin. The amount of pure heparin depends on the diameter and length and will be in accordance with the manufacturer's specifications.
Trial: NCT05444738
Drug: oral lollipop with placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately before drug administration, a blood sample (5ml) is collected. For placebo administration, participants will be instructed to suck the placebo lollipop for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to taking another blood sample (5ml). Participants then start the anti-saccade attention task 45 minutes after placebo administration.
Trial: NCT05335252
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 caplet 2x daily for 7 days
Trial: NCT06370039
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Ophthalmic Solution
Trial: NCT05515328
Drug: [¹⁴C] BI 685509 formulation 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[¹⁴C\] BI 685509 formulation 1
Trial: NCT05515328
Drug: [¹⁴C] BI 685509 formulation 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[¹⁴C\] BI 685509 formulation 2
Trial: NCT06452693
Drug: TQA3038 injection/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQA3038 is a Anti-Hepatitis B virus (HBV) drugs.
Trial: NCT06452693
Drug: Nucleotide drugs Control group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleotide drugs are nucleoside reverse transcriptase inhibitors.
Trial: NCT05531500
Drug: Injection
RxNorm normalized name: Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of local anesthetic + steroids
Trial: NCT04846231
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).
Trial: NCT05253417
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants take four (4) placebo capsules.
Trial: NCT06135948
Drug: Extra dose of L-thyroxine, 25 mcg during Ramadan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra dose of L-thyroxine, 25 mcg during the month of Ramadan
Trial: NCT04548973
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2ml normal saline
Trial: NCT05030584
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo orally once daily.
Trial: NCT06262438
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction course 1: Methotrexate (MTX) Intrathecal therapy (IT) prophylaxis is age-adjusted. If MTX is given at diagnosis omit IT therapy on day 6 unless in case of CNS involvement (CNS3). For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently. For children with CNS2, CSF must be investigated on day 22; if leukemic cells persist, treat as CNS3.~Induction course 2, Day 1: MTX (IT) prophylaxis is age-adjusted. For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently.~Consolidation course 1, Day 1: MTX (IT) prophylaxis is age-adjusted. For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently.~Consolidation course 2 and 3, Day 1 (only if no allo-SCT is done): MTX (IT) prophylaxis is age-adjusted. For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently.
Trial: NCT04280003
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous solution, same appearance stem cells solution